Angeles Alvarez Secord, MD
My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.
Education and Training
- Resident, Obstetrics & Gynecology, Duke University, 1994 - 1998
- M.D., University of Washington, 1994
- Duke University Medical Center, Masters of Health Sciences in Clinical Research, 2005-2011
Dr. Secord's research interests include elucidating the underlying genetic biology of angiogenesis in ovarian cancer, innovative clinical trial design, development of novel targeted therapies for personalized medicine, identification of biomarkers to direct anti-neoplastic therapy, and the incorporation of patient-reported outcomes in clinical trials. She has studied the regulation of angiogenesis in ovarian cancer for approximately 20 years and has recently extended our research to include the immunophenotype of the tumor microenvironment.
Selected Grants and Awards
- NCI National Clinical Trials Network (UG1)
- SGNTV-002: Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen
- A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician¿s Choice in Participants with Adva
- Atezo NACT for Ovarian Cancer
- GOG 3018: OVAL
- GOG 3025: DUO-O
- GOG 3020: ATHENA
- Atezo NACT for Ovarian Cancer (Bio- Markers Lab Clinc Resch)
- GOG3015 Foundation Study ( Atezo Frontline)
- Phase 2 Trial of Dose Dense (Weekly) Paclitaxel with Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer
- Tapimmune FRV-004
- GOG3005-ABB VIE Protocol M13-694
- A Pilot Study Investigating the Effect of Pembrolizumab on the Tumoral Immunoprofile of Cancers of Muellerian Origin
- Quadra Study
- TESARO LUNG AND ENDOMETRIAL CANCER PRACTICUM
- A Phase 2 Randomized Double-Blind Trial of Maintenance with Niraparib vs Placebo
- NRG ONCOLOGY NETWORK GROUP OPERATIONS CENTER
- NCI National Clinical Trials Network U10 (Year 5)
- Women with BRCA-mutated Advanced Stage Ovarian Cancer
- GOG3016 Foundation Study ( Atezo Frontline)
- Apera ARP-407
- Lynparza Open Acess Olaparib
- Predictive value of the IL6 pathway to direct anti-angiogenic therapy in advanced ovarian cancer
- Assessing the relevance of weighted values in the ASCO value framework in ovarian cancer patients
- Blood-based Angiome Profiling to Direct Bevacizumab Therapy in Ovarian Cancer
- Tesaro Ovarian Cancer Practicum
- A Phase III Randomized, Double-Blind, Placebo Controlled Multicrentre Study of Olaparib Maintenance Monotherapy
Secord, Angeles Alvarez, Michael McCollum, Brittany A. Davidson, Gloria Broadwater, Robert Squatrito, Laura J. Havrilesky, Anne C. Gabel, et al. “Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer..” Gynecol Oncol 153, no. 3 (June 2019): 555–61. https://doi.org/10.1016/j.ygyno.2019.03.246.
Deutsch, Gary B., Jeremiah L. Deneve, Mazin F. Al-Kasspooles, Valentine N. Nfonsam, Camille C. Gunderson, Angeles Alvarez Secord, Phillip Rodgers, et al. “Intellectual Equipoise and Challenges: Accruing Patients With Advanced Cancer to a Trial Randomizing to Surgical or Nonsurgical Management (SWOG S1316)..” Am J Hosp Palliat Care, May 23, 2019. https://doi.org/10.1177/1049909119851471.
Veade, Ashley E., Jonathan Foote, Jessie Ehrisman, Gloria Broadwater, Brittany A. Davidson, Paula S. Lee, Angeles Alvarez Secord, Andrew Berchuck, and Laura J. Havrilesky. “Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma..” World J Surg Oncol 17, no. 1 (May 10, 2019). https://doi.org/10.1186/s12957-019-1620-x.
Lim, Stephanie L., Laura J. Havrilesky, Ashraf S. Habib, and Angeles Alvarez Secord. “Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy..” Gynecol Oncol 153, no. 2 (May 2019): 376–80. https://doi.org/10.1016/j.ygyno.2019.01.025.
Moore, K. N., A. A. Secord, and M. A. Geller. “Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial (vol 20, pg 636, 2019).” Lancet Oncology 20, no. 5 (May 1, 2019): E242–E242.
Moore, Kathleen N., Angeles Alvarez Secord, Melissa A. Geller, David Scott Miller, Noelle Cloven, Gini F. Fleming, Andrea E. Wahner Hendrickson, et al. “Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial..” Lancet Oncol 20, no. 5 (May 2019): 636–48. https://doi.org/10.1016/S1470-2045(19)30029-4.
Moore, Kathleen, John K. Chan, Angeles Alvarez Secord, Manish R. Patel, Timothy Callahan, Wei Guo, and Zhi-Yi Zhang. “Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer..” Cancer Chemother Pharmacol 83, no. 4 (April 2019): 717–26. https://doi.org/10.1007/s00280-019-03774-w.
Puechl, Allison M., James Edwards, Anuj Suri, John Nakayama, Sarah Bean, Paola Gehrig, Erin Saks, et al. “The association between progesterone receptor expression and survival in women with adult granulosa cell tumors..” Gynecol Oncol 153, no. 1 (April 2019): 74–79. https://doi.org/10.1016/j.ygyno.2019.01.016.
Dottino, Joseph A., Haley A. Moss, Karen H. Lu, Angeles A. Secord, and Laura J. Havrilesky. “U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis..” Obstet Gynecol 133, no. 4 (April 2019): 795–802. https://doi.org/10.1097/AOG.0000000000003171.